Compare KYMR & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KYMR | KRYS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.6B |
| IPO Year | 2020 | 2017 |
| Metric | KYMR | KRYS |
|---|---|---|
| Price | $106.49 | $327.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 12 |
| Target Price | $139.35 | ★ $392.11 |
| AVG Volume (30 Days) | ★ 791.6K | 264.1K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 3.62 |
| Revenue | $39,211,000.00 | ★ $389,130,000.00 |
| Revenue This Year | $167.23 | $29.00 |
| Revenue Next Year | N/A | $28.44 |
| P/E Ratio | ★ N/A | $88.72 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $55.26 | $183.03 |
| 52 Week High | $130.05 | $382.54 |
| Indicator | KYMR | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 45.22 |
| Support Level | $100.63 | $318.87 |
| Resistance Level | $121.24 | $371.16 |
| Average True Range (ATR) | 5.07 | 10.24 |
| MACD | -0.31 | -0.39 |
| Stochastic Oscillator | 36.08 | 29.01 |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.